PT-141 (Bremelanotide): Uses, Dosage, Preparation, Effects, and Side Effects

What Is PT-141?

PT-141, also known as bremelanotide, is a melanocortin receptor agonist that acts primarily through the central nervous system (MC3R/MC4R pathways). It is clinically approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Sixpex bremelanotide

Key points:

• Works centrally rather than through direct genital blood flow

• Can increase sexual desire and reduce distress related to low desire in selected patients

• Not intended as a general sexual performance enhancer

• Not indicated for men or postmenopausal women

• Cardiovascular monitoring is important due to transient blood pressure effects

---

Dosage Logic

PT-141 is administered subcutaneously on an as-needed basis, timed before sexual activity.

Standard Clinical Dose

• 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity

Frequency Limits

• No more than 1 dose within 24 hours

• No more than 8 doses per month

Effectiveness is assessed over multiple uses. If meaningful benefit is not achieved after an appropriate trial, continued use may not be warranted.

When Use Should Be Avoided or Stopped

• Uncontrolled hypertension or known cardiovascular disease

• Severe or persistent nausea or vomiting

• Clinically concerning blood pressure or heart-related symptoms

• Lack of meaningful improvement after appropriate trial

---

Solution Preparation (Conceptual)

PT-141 is supplied as a sterile, clear solution in a prefilled autoinjector. Each device contains 1.75 mg bremelanotide (1.89 mg bremelanotide acetate) in 0.3 mL.

Conceptual Solution Logic:

• Fixed dose delivered per autoinjector

• Concentration: 1.75 mg ÷ 0.3 mL

• No mixing or reconstitution is needed

---

Timeline of Effects

Timing of Single Dose

• Administer at least 45 minutes before sexual activity

• Early adverse effects (e.g., nausea) may occur, especially on initial doses

Short-Term Course

• Nausea is common initially and may lessen with repeated use

• Overall benefit is assessed over multiple, appropriately timed doses

Expected Outcomes

• Improved sexual desire

• Reduced distress related to low desire

• Results vary depending on diagnosis and biopsychosocial factors

• Not intended for general sexual performance enhancement

---

Side Effects

Most Common

• Nausea (most notable with early doses)

• Flushing

• Injection-site reactions

• Headache

• Vomiting

Clinically Important Considerations

• Transient increases in blood pressure

• Potential hyperpigmentation due to melanocortin activity

Strategies to Reduce Side Effects

• Do not exceed 1 dose per 24 hours

• Do not exceed 8 doses per month

• Reassess or discontinue if nausea is persistent

• Monitor cardiovascular status in at-risk patients

Higher-Risk Individuals

• Uncontrolled hypertension

• Known cardiovascular disease

• Individuals prone to severe nausea/vomiting

---

Conclusion

PT-141 (bremelanotide) is a centrally acting melanocortin receptor agonist used as needed for HSDD in premenopausal women. Its 1.75 mg subcutaneous dose is delivered via a prefilled autoinjector, with strict limits on frequency to ensure safety.

Key takeaways:

• Central mechanism via MC3R/MC4R pathways

• Fixed-dose, prefilled autoinjector

• Nausea and cardiovascular effects are primary safety considerations

• Appropriate patient selection and monitoring are critical for balancing benefit and safety